I

Iambic Therapeutics pricing

No price is published, but the deal shape is. Iambic does not license its platform: it develops its own pipeline and enters multi year discovery collaborations, announced with AbbVie in September 2026 and Bayer in June 2026. The structure of the terms is public, combining upfront payments, research cost coverage, technology access fees, milestone payments and royalties on net sales, and one reported agreement carries success based payments the company describes as potentially exceeding $1.7 billion.

Pricing terms

How Iambic Therapeutics pricing works

Pricing model
Collaboration agreements combining upfront payments, research cost coverage, technology access fees, milestone payments, and royalties.
Implementation
Not applicable. Engagements are research collaborations rather than software deployments.

That figure is the full milestone stack across a multi program agreement rather than a contract value or a price, and it describes what one partner negotiated. No rate card, unit of charge or per program economics are published, and neither is what technology access covers or how rights to platform designed molecules are split.

Compared on price

Iambic Therapeutics pricing against its alternatives

Published prices for Iambic Therapeutics and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.

All Iambic Therapeutics alternatives →

Questions

Iambic Therapeutics pricing, answered

How much does Iambic Therapeutics cost?

Partnership structured, no list pricing. Iambic does not license its platform: it develops its own pipeline and enters multi year discovery collaborations, announced with AbbVie in September 2026 and Bayer in June 2026.

Does Iambic Therapeutics charge an implementation fee?

Not applicable. Engagements are research collaborations rather than software deployments.